Article published in the La Primera newspaper, written by Roberto Lopez, Coordinator of AIS. A sector of the pharmaceutical industry says that it is committed to defend the health of the population for which require duplicate controls of quality and relaxing some regulations of drugs. If health care were its purpose, the Online pharmacy industry should recall of many products have no proven therapeutic effectiveness, and that they are only there because sold and produced important utilities; or combinations of two or more drugs without technical justification that prevents treatment adjusted to each patient. Conversely, one of the provisions that this industrial sector supports the Bill N 995-2011-CR, amending the law of medicine 29459 is that those who seek his re-enrollment for the health record and medicines according to the law currently in force must sustain them with studies of efficacy and safety, must only submit information about safety and effectiveness. The same Bill has that certification of good practices of manufacture (BPM) of a high health surveillance as United States country is only valid for those plants that are in its territory. It is worth remembering that the United States FDA, for example, certifies BPM to the India pharmaceutical plants so that they can enter their products to the U.S. market.
On the other hand, this project requires unnecessary quality controls, subtracting utility to the fact that the DIGEMID certify in BPM to plants abroad where medicinal products are imported. In the absence of sufficient accredited laboratories in the country to do what the project proposes, is would create a bottleneck for entry and marketing of imported medicines. In this scenario, the national pharmaceutical companies appear as the ability to perform quality control services in the national territory, with what would be the figure that companies which produce and market drugs would make such control to the products of their competitors. Both cases could lead to a reduction in the flow of drugs, less competition, likely shortage and high prices. Television programs have shown the characters that they are behind this initiative that it has nothing to do with the health of the population, but yes, with commercial interests. At the time of a decision, Congress should consider that resulting regulations may restrict competition and, on the other hand, perpetuate the permanence in the market for products that, beyond that are many years in the market, have not tested efficacy and/or its therapeutic drug rationality.